INTRODUCTION
In 1972, Rossomondo (1) published the first report on the use of sodium pertechnetate 99m Tc for evaluating the lacrimal drainage system. The dose administered was 1.85MBq to 3.7 MBq (50 to 100 µCi) with a scintigraphic procedure of 25 minutes duration and excellent visualization of the external lacrimal system. Applications in other medical fields were suggested, the main point being that the anatomy of the structures involved were not altered, and important physiological parameters could possibly be solved in an elegant, non-irritating manner. Before, radiopaque dyes had been utilized for imaging the lacrimal drainage system (dacryocystogram) which is uncomfortable, time consuming and deforming on anatomical structures. Blanksma (2) . Gamma scintigraphy can be of benefit in providing data (3): · on rate and extent of drug absorption · for "proof of concept" · for explaining drug and/or formulation effects · by use of sequential scintigraphic images ("time-lapse photography") · that in vivo performance is in agreement with the intended application · concerning delivery of the right amount of drug in the right place at the right time · that may overcome the poor predictability of in vitro studies Essential to the design of a radiopharmaceutical agent is the chemistry of the desired radiometaled chelate. The introduction of 99m Tc as a labelling agent by chelation has changed the practice of nuclear medicine. The practice of chelation in medicine is not new (4) . In 1951, it was suggested that "salicylates" are capable of chelation and might, therefore, possess therapeutic properties. Aspirin aluminum is a known drug entity and incorporated in the Japanese Pharmacopoeia XIII. A very known reaction in the field of biochemistry and pharmacy is the appearance of a purple color in a weakly acid solution in the presence of a salicylate ion when ferric salts are added (5) . In this manner, a quantitative estimate in a biological sample can be given in a relatively short time. Chelating ability of the ferric and ferrous cation with salicylic acid has been reported in favor of the ferric cation in a ratio of 400 to 1 (6) .
Spectroscopic studies have been performed on salicylic acid, salicylamide and acetylsalicylic acid as to which spatial configuration favors these drugs most. Calculations have made it plausible that the ß-form is the preferred configuration. In this orientation, the carboxylic hydroxyl group is directed towards the enolic hydroxyl group (7) . Further research (8) has deepened the mechanism of complexation of 99m Tc with "aspirin-like" molecules. Diflunisal (5-(2',4'-difluorophenyl)salicylic acid) inhibits the COX-1 enzyme in the same degree as sodium salicylate and approximately 20% less than flurbiprofen with the same level (80%) of COX-2 inhibition (9,10). The authors used this well defined pharmacological assay to assess the potential of S(+) flurbiprofen as a cyclooxygenase (COX) inhibitor formulated as an eyedrop (11) . Acetylsalicylic acid showed the same degree of inhibition for COX-1 and COX-2 as flurbiprofen. The disadvantage of using acetylsalicylic acid, however, is its instability in solution (12) .
In our study, we chose the drug, diflunisal, as a representative for the mechanism of complexation as described above and sharing pharmacologic resemblance with the drug, flurbiprofen, as an NSAID in being fluorinated and possessing a biphenyl ring. Tc generator (Mallinckrodt). Diflunisal (product number: D-3281; lotnr:95H0528) was purchased from Sigma (St Louis, Mo, USA), Stannous Tartrate 500 microgram (BN040701; lyophilized) was purchased from IV DIRECT LTD (London, UK). The ophthalmic solution was dispensed by a Hamilton microliter syringe (50 microliter; art.nr.:3038015). Thin-layer chromatography material consisted of Whatman paper No17 (Tamson no 194K01) and ITLC-SG (Gelman no 61886); scanning was performed with a Raytest chromatogram scanner equipped with miniGITA software.
MATERIALS and METHODS

Gamma camera and computer system
Formulation of Diflunisal Eyedrops
Preparation of the diflunisal eyedrops proceeds by addition of 50 mg diflunisal to a part of the available 0.3 M sodium chloride solution. By addition of approximately 1 ml of 1M sodium hydroxide, a clear solution is obtained. The pH was adjusted between 7.0 -7.5 before adding up to 100.0 ml. The final solution was filtered through a 0.22 micron filter. All diflunisal preparations were stored in glass containers. No preservative was added.
Analytical Assay
By use of HPLC combined with Diode Array Detection as described by Uges et al. (13) quality of the ophthalmic solution was assayed. In short, a reversed phase RP-18 endcapped 5µm. 125x4mm column is used (Merck Darmstadt/Amsterdam, Catalog number: 21568); mobile phase: acetonitrile 470 ml(Lichrosolve) phosphoric acid/triëthylamine 530 ml buffer pH 3.3 is used. Content was analysed by spectrophotometric assay (Varian CARY 3) at 255 nm.
Patient Setting
In this representative study, investigations were carried out in one subject (vS, 1944) . Comfortably seated upright in a chair, a drop of ophthalmic solution (50 microliter) was placed into the conjunctival sac at the lateral canthus. The head was positioned with the inner canthus less than 5 mm from the pinhole collimator. Sufficient resolution could be obtained for the eye, canaliculi and lacrimal sac. Scintigraphic images were made over a 20-minute period. In two separate sessions (spaced by 1 month), the ophthalmic 99m Tc-diflunisal solution and a pertechnetate sodium solution were investigated. In both instances, the left eye was used. Free passage of the lacrimonasal duct had been assured beforehand by the test of Anel. Application of the eyedrop was experienced as a transient prickling sensation.
Preparation of 99m
Tc-Diflunisal and Pertechnetate Sodium Eyedrops 99m Tc-Diflunisal Eyedrops Sodium chloride 0,9% (low in oxygen content) is added to the vial containing 500 micrograms stannous tartrate. The contents of the vial are swirled cautiously. Next, the calculated amount of sodium pertechnetate activity is added (1ml=60 MBq) followed by the addition of 1ml of 0.05% diflunisal ophthalmic solution. The total contents (3 ml) is boiled for 10 minutes followed by radiochemical quality control of 99m Tc-diflunisal. Labeling is set at 75 -80% or more.
Sodium Pertechnetate Eyedrops
Preparation of the sodium pertechnetate eyedrop was analogues to the 99m Tc-diflunisal preparation differing in substitution by sodium chloride 0.9%. of the diflunisal solution. This solution contained 60 MBq in 3 ml solution (1 MBq in 50 microliters). Radiochemical quality control of pertechnetate was performed with purity set at 95% or more.
Analytical quality control for radiochemical purity
Radiochemical purity of a radiopharmaceutical is defined as the proportion of total radioactivity in the desired compound. Analysis is performed by the two-strip mini-chromatography method as described in (14) . In figure 1 , the basic outline of the procedure is presented. Likewise, a spot of the same solution is deposited on the ITLC-SG strip and developed in phosphate buffered salt (PBS; pH 7.4) or 0.9% sodium chloride. The chromatography strip is developed in the chosen solvent and analyzed by a chromatography scanner recording radioactivity along the length of the strip. The percentage of radiochemical impurity is calculated from the ratio of radioactivity associated with the impurity compared with the radioactivity of the total strip.
RESULTS
ANALYTICAL ASSAY
HPLC and UV Spectrophotometry
Quality control by HPLC of the ophthalmic diflunisal 0.05% solution displayed no degradation peaks (figure 2) with a content of 99.6% diflunisal measured by quantitative spectrophotometric analysis. 
Radiopharmaceutical Quality Control
In figures 3, 4 and 5, examples of radiopharmaceutical quality control by thin-layer chromatography are depicted. Labeling efficiency for diflunisal, measured by the thin-layer chromatography system as described, resulted in 77% when sodium chloride 0,9% was used and 83% when PBS pH7.4 was the solvent. Purity of pertechnetate, used in the ophthalmic solution, was 96%. Figure 6 demonstrates the activity seen in frame 16 and the graphic illustration of counts versus time (whole session). Frame 16 signals the end of the eyes-closed sequence. Some activity is still left at the point of instillation of the eye drop. At the end of the sequence, all activity seems present in the lacrimonasal ductus. When one analyzes frame 117, residual activity (figure 7) distinct from baseline activity is present in the area of pupil and iris. This is displayed in the accompanying graph.
Scintigraphic Assay
Comparing the frames, taken at the same time sequence, obtained with 99m Tc-diflunisal and pertechnetate, a difference in scintigraphic exposure can be seen ( figure 8 ). 
TcDiflunisal
Calculation of the activity as counts per pixel for the area designated as pupil, iris and conjunctiva (excluding the lacrimonasal ductus), leads to a graph (figure 9) distinguishing a higher level of activity in the iris than the pupil. Correction for natural decay of 99m Tc has been taken into account. Gy per Bq or 0.04 mGy (15) . This is far below the dose known to produce radiation cataract (16) . Scintigraphic evidence in the nasal cavity can be seen within one minute. As reported in the literature, closing of the eye will slow the process of drainage. After opening the eye, the tear flow will proceed at a normal physiological value of approximately 1 microliter per minute. After instillation of an eye drop, the extra volume will be rapidly eliminated in the first two minutes. This will be followed by a bi-exponential decay (initial phase of 2 -5 minutes; basal phase from 7 minutes onward) where the tear flow will be 1.4 and approximately 1 microliter per minute, respectively. Any variation from these principles could indicate a disturbance in the delicate balance of the lacrimal system (17, 18, 19) .
In figure 9 , a display of counts per pixel is given for the structures of pupil, iris and conjunctiva. The amount of labeled diflunisal that has entered the eye and is visible on the iris in frame 117 can be estimated by calculating the amount instilled, 8.35 microgram in 50 microliters, equivalent to 2900 counts. The pupil is represented by 0.15 counts per pixel (total pixel count: 79) and the iris by 0.30 (total pixel count: 589). The estimated amount that has entered the eye through the cornea and is visibly attached to the iris will have to be corrected for the amount per pixel Tissue concentration-time profiles for the iris-ciliary body closely resembles those for stroma-endothelium and aqueous humor. Peak concentration time for instilled pilocarpine was reached at 20 minutes (20) . The initial total volume of distribution after application of an eye drop is reported to be 350 microliters. This encompasses the aqueous humor volume and the cornea (21) . In this case 254 nanograms will be in 350 a microliter solution. This equates to 3x10 -6 M for diflunisal. For flurbiprofen, it was found that the COX-1 enzyme in the human iris is inhibited 100% by a 10 -7 M flurbiprofen solution (11) . This will also suffice for inhibition of the COX-1 enzyme by diflunisal (9) .
CONCLUSION
In vitro experiments (22, 23) , using a corneal perfusion device with simulated physiologic tear turnover as in vivo, or a three-dimensional tissue constructed to investigate drug penetration across the cornea, have been published but lack the realtime complex interplay in dynamics of tear fluid, tear turnover, aqueous humor and mechanical stress of the eyelids. This report provides scintigraphic evidence of the iris/ciliary body with use of a 99m Tc-labelled NSAID, diflunisal.
